Celldex Therapeutics Inc. (NASDAQ:CLDX) shares saw unusually-high trading volume on Friday . Approximately 3,772,675 shares traded hands during trading, an increase of 115% from the previous session’s volume of 1,751,799 shares.The stock last traded at $3.88 and had previously closed at $4.16.

CLDX has been the subject of several recent analyst reports. Jefferies Group increased their price objective on Celldex Therapeutics to $5.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Wedbush reiterated a “neutral” rating and set a $3.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Finally, Cowen and Company reiterated an “outperform” rating and set a $12.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, June 7th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $10.75.

The firm’s market capitalization is $397.15 million. The firm’s 50 day moving average price is $4.57 and its 200 day moving average price is $4.75.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. The business had revenue of $1.39 million for the quarter, compared to the consensus estimate of $0.96 million. The business’s revenue was down 36.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.33) earnings per share. Equities research analysts predict that Celldex Therapeutics Inc. will post ($1.34) EPS for the current year.

An institutional investor recently raised its position in Celldex Therapeutics stock. Rhumbline Advisers boosted its stake in shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) by 4.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 108,426 shares of the biopharmaceutical company’s stock after buying an additional 5,110 shares during the period. Rhumbline Advisers owned about 0.11% of Celldex Therapeutics worth $1,700,000 at the end of the most recent quarter.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.